Jonathan Douglas Santoro, MD
Neurology · Los Angeles
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Childrens Hospital Los Angeles Medical Group Inc · 288 clinicians in this group
Hospitals listed: Children'S Hosp of Los Angeles. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Santoro’s office at (323) 361-8408 to ask if they take your plan before you enroll.
California Medical Board record
Licence A131807 · Current
Licensed to practise in California · since 2014 · expires 2028-05-31 · Tulane University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Children'S Hosp of Los AngelesLos Angeles, CAChildren · Voluntary non-profit - Private · Has an emergency departmentPart of Childrens Hospital Los AngelesNo overall ratingNo measure marked better or worse than the national rate
Original Medicare doctor bills
$2,969
Medicare paid this office $2,969 for 18 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
Who their Medicare patients are
18 Original Medicare patients in 2024. Average age 28 · Under 65 100% · 85 and older 0% · Also on Medicaid 100% · Health risk score 1.11. At or below the middle of the specialty; the typical neurology clinician is at 1.61.
The office billed $16,440, Medicare allowed $4,369 and paid $2,969; for 50 services of 4 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Medicaid work
$19,282 in 2024
Medicaid paid $19,282 for 108 billed services this clinician did in 2024, up to 16 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 41 | $16,484 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 16 | $1,350 |
| Long return visit (40+ min) | 12 | $796 |
| Service | 12 | $409 |
| Service | 27 | $243 |
| 2024 | 108 | 5 | 16 | $19,282 |
| 2023 | 317 | 5 | 17 | $20,527 |
| 2022 | 236 | 4 | 18 | $17,685 |
| 2021 | 393 | 4 | 22 | $32,128 |
| 2020 | 395 | 5 | 28 | $38,723 |
| 2019 | 154 | 3 | 21 | $11,619 |
See the largest Medicaid services in earlier years
2023
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 21 | $8,449 |
| Long return visit (40+ min) | 54 | $5,751 |
| Service | 81 | $2,728 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 26 | $2,199 |
| Service | 135 | $1,400 |
2022
| Long return visit (40+ min) | 94 | $12,979 |
| Service | 64 | $2,182 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 30 | $2,073 |
| Service | 48 | $451 |
2021
| Long return visit (40+ min) | 176 | $23,779 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 72 | $4,731 |
| Service | 92 | $3,103 |
| Service | 53 | $515 |
2020
| Long return visit (40+ min) | 151 | $19,087 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 126 | $8,292 |
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 17 | $6,620 |
| PROLNG SVC I/P/OBS 1ST HOUR | 61 | $3,377 |
| Service | 40 | $1,347 |
2019
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 95 | $6,246 |
| Long return visit (40+ min) | 30 | $3,757 |
| PROLNG SVC I/P/OBS 1ST HOUR | 29 | $1,616 |
Drugs they prescribed that Part D paid
$766,932
Pharmacies billed $766,932 in 2024. Most of that is three immune-globulin drugs at $6,000–$11,000 a fill for a small number of people.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 210) in 2024. At or below the middle of the specialty; the typical neurology clinician is at 0%.
96 generic and 114 brand-name prescriptions · $766,932 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Octagam | Immune globulin | 74 | $478,825 | $6,471 |
| Panzyga | Immune globulin | 20 | $220,088 | $11,004 |
| Privigen | Immune globulin | 11 | $63,301 | $5,755 |
| Lorazepam | None | 38 | $374 | $10 |
Year by year
| 2024 | 210 | 16 | 0% (0) | 54% | $766,932 |
| 2023 | 60 | None | 0% (0) | 28% | $172,297 |
| 2022 | 26 | None | 0% (0) | None | $6,745 |
| 2021 | 16 | None | 0% (0) | 0% | $8,102 |
| 2019 | 61 | 13 | 0% (0) | None | $54,805 |
| 2018 | 28 | 13 | 0% (0) | None | $1,443 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 2 drugs
| Lorazepam | 11 | $322 | $29 |
| Guanfacine | 11 | $313 | $28 |
2021: 1 drug
| Dalfampridine Er | 13 | $8,067 | $621 |
2019: 1 drug
| Baclofen | 18 | $742 | $41 |
Money from drug and device companies
$13,000 in 2025
| 2025 | 6 | 11 | $12,488 | $13,000 |
| 2024 | 4 | 5 | $9,588 | $9,835 |
| 2023 | 5 | 7 | $1,696 | $2,040 |
| 2022 | 8 | 14 | $7,570 | $7,846 |
| 2021 | 6 | 8 | $6,950 | $7,105 |
| 2019 | 3 | 6 | None | $1,313 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Ucb Sa | Rystiggo | $10,280 | 3 payments
|
| Amgen | Blincyto | $2,058 | 1 payment
|
| TG Therapeutics | Briumvi | $336 | 3 payments
|
| Biogen | Tysabri | $214 | 2 payments
|
| Ucb | None | $86 | 1 payment
|
| Cycle Pharmaceuticals | Tascenso Odt | $26 | 1 payment
|
See all 11 published payments
| Ucb Sa | Consulting · 2025-12-19 | None | $1,640 |
| Amgen | Consulting · 2025-11-04 | Blincyto | $2,058 |
| TG Therapeutics | Meals · 2025-10-28 | Briumvi | $88 |
| Biogen | Meals · 2025-09-25 | Tysabri | $64 |
| Ucb | Meals · 2025-09-11 | None | $86 |
| TG Therapeutics | Meals · 2025-08-11 | Briumvi | $112 |
| TG Therapeutics | Meals · 2025-08-11 | Briumvi | $136 |
| Biogen | Consulting · 2025-05-15 | Tysabri | $150 |
| Ucb Sa | Consulting · 2025-03-28 | Rystiggo | $7,000 |
| Ucb Sa | Consulting · 2025-03-14 | None | $1,640 |
| Cycle Pharmaceuticals | Meals · 2025-01-22 | Tascenso Odt | $26 |
See earlier years (2024, 2023, 2022, 2021, 2019)
2024: $9,835
| Cycle Pharmaceuticals | Ormalvi | $6,091 | 2 payments
|
| Ucb Sa | None | $3,075 | 1 payment
|
| Alnylam Pharmaceuticals | None | $533 | 1 payment
|
| TG Therapeutics | Briumvi | $136 | 1 payment
|
2023: $2,040
| Cycle Pharmaceuticals | Nityr | $1,079 | 1 payment
|
| Marinus Pharmaceuticals | None | $467 | 1 payment
|
| Biogen | Tysabri | $393 | 3 payments
|
| Novartis Pharmaceuticals | None | $56 | 1 payment
|
| Ucb | None | $45 | 1 payment
|
2022: $7,846
| Ucb Sa | None | $4,070 | 2 payments
|
| Cycle Pharmaceuticals | Nityr | $1,500 | 1 payment
|
| Marinus Pharmaceuticals | None | $1,483 | 3 payments
|
| ZOLL Medical | None | $517 | 1 payment
|
| Biogen | Vumerity | $156 | 3 payments
|
| Novartis Pharmaceuticals | Kesimpta | $51 | 2 payments
|
| Alexion Pharmaceuticals | Soliris | $39 | 1 payment
|
| Ucb | None | $30 | 1 payment
|
2021: $7,105
| Ucb Sa | None | $3,280 | 1 payment
|
| Horizon Therapeutics plc | Uplizna | $2,500 | 1 payment
|
| Alexion Pharmaceuticals | Soliris | $1,063 | 2 payments
|
| Biogen | Tysabri | $182 | 2 payments
|
| Ucb | None | $41 | 1 payment
|
| Novartis Pharmaceuticals | Kesimpta | $38 | 1 payment
|
2019: $1,313
| Genzyme | No Product Discussed | $1,000 | 1 payment
|
| Biogen | Tysabri | $279 | 4 payments
|
| Novartis Pharmaceuticals | Mayzent | $33 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Novartis Pharmaceuticals Corporation · A 2-Year Randomized, 3-Arm, Double-Blind, Non-Inferiority Study Comparing the Efficacy and Safety of Ofatumumab and Siponimod Versus Fingolimod in Pediatric Patients With Multiple Sclerosis Followed By An Open-Label Extension · 2025 | Their institution | $558,482 |
| Novartis Pharmaceuticals Corporation · A 2-Year Randomized, 3-Arm, Double-Blind, Non-Inferiority Study Comparing the Efficacy and Safety of Ofatumumab and Siponimod Versus Fingolimod in Pediatric Patients With Multiple Sclerosis Followed By An Open-Label Extension · 2024 | Their institution | $457,212 |
| Novartis Pharmaceuticals Corporation · A 2-Year Randomized, 3-Arm, Double-Blind, Non-Inferiority Study Comparing the Efficacy and Safety of Ofatumumab and Siponimod Versus Fingolimod in Pediatric Patients With Multiple Sclerosis Followed By An Open-Label Extension · 2023 | Their institution | $346,967 |
| Novartis Pharmaceuticals Corporation · A 2-Year Randomized, 3-Arm, Double-Blind, Non-Inferiority Study Comparing the Efficacy and Safety of Ofatumumab and Siponimod Versus Fingolimod in Pediatric Patients With Multiple Sclerosis Followed By An Open-Label Extension · 2022 | Their institution | $22,094 |
| Biogen, Inc. · Study To Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants · 2021 | Their institution | $14,140 |
| Boehringer Ingelheim International GmbH · Non-Imp Clinical Study To Generate Data on the Natural History of Disease, Biomarkers, and Relevance of Clinical Endpoints in Patients With Selected Type 1 Interferonopathies · 2025 | Their institution | $12,141 |
| Boehringer Ingelheim International GmbH · Natural History Study of Selected Type 1 Interferonopathies Based on Data of Medical Records · 2025 | Their institution | $10,555 |
| Biogen, Inc. · A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3-Arm, Parallel-Group Study in Pediatric Subjects Aged 10 Through 17 Years To Evaluate the Efficacy and Safety of Bg00012 and Biib017 for the Treatment of Relapsing-Remitting Multiple Sclerosis · 2023 | Their institution | $6,413 |
| UCB, Inc. · Attack Phenotypes and Disease Course in Pediatric Mogad · 2022 | This clinician | $2,800 |
| UCB, Inc. · Copy of Roz-Sma-055584 Attack Phenotypes and Disease Course in Pediatric Mogad · 2022 | This clinician | $2,800 |
| UCB, Inc. · Exploring the Patient Pathway From First Symptoms To Diagnosis: Results From An International Survey of Patients With Myelin Oligodendrocyte Glycoprot · 2022 | This clinician | $820 |
| Novartis Pharmaceuticals Corporation · Agnos: An 18-Month, Open-Label, Multi-Center Study To Assess the Effect of Ofatumumab 20mg Sc Monthly in Treatment Nave, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes · 2023 | Their institution | $659 |
| Novartis Pharmaceuticals Corporation · Agnos An 18-Month, Open-Label, Multi-Center Study To Assess the Effect of Ofatumumab 20mg Sc Monthly in Treatment Naive, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes · 2022 | Their institution | $478 |
| Biogen, Inc. · Study To Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants · 2020 | Their institution | $193 |
| Boehringer Ingelheim International GmbH · Non-Imp Study · 2024 | Their institution | $123 |
Professional record
- NPI
- 1053754614
- Licence
- CA A131807California A131807: Current · expires 2028-05-31
- Trained
- Tulane University School of Medicine, 2013
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2084N0402X (2084N0402X)
- Mailing address
- 725 Welch Rd, Palo Alto, CA, 94304
- NPI first listed
- 2013-04-14
- NPI last updated
- 2019-12-13
- NPI record certified
- 2019-12-13
This is when the NPI record was last certified, not a medical board exam.